Biomea Fusion announces presentation of icovamenib preclinical, clinical data

TipRanks03-25

Biomea Fusion (BMEA) announced the presentation of preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies & Treatments for Diabetes 2025 Conference in Amsterdam, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522507626?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-25 20:50","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2522507626","market":"nz","top_or_hot":-1,"title":"Biomea Fusion announces presentation of icovamenib preclinical, clinical data","media":"TipRanks","content":"<div>\n<p>Biomea Fusion (BMEA) announced the presentation of preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies & Treatments for Diabetes 2025 Conference in Amsterdam, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biomea-fusion-announces-presentation-icovamenib-125053055.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biomea Fusion announces presentation of icovamenib preclinical, clinical data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiomea Fusion announces presentation of icovamenib preclinical, clinical data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-25 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biomea-fusion-announces-presentation-icovamenib-125053055.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biomea Fusion (BMEA) announced the presentation of preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies & Treatments for Diabetes 2025 Conference in Amsterdam, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biomea-fusion-announces-presentation-icovamenib-125053055.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://finance.yahoo.com/news/biomea-fusion-announces-presentation-icovamenib-125053055.html","article_id":"2522507626","we_media_id":null,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biomea-fusion-announces-presentation-icovamenib-125053055.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2522507626","pubTimestamp":1742907053,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Biomea Fusion (BMEA) announced the presentation of preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies & Treatments for Diabetes 2025 Conference in Amsterdam, ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","BMEA":"Biomea Fusion, Inc.","BK4585":"ETF&股票定投概念"},"translate_title":"Biomea Fusion宣布展示icovamenib临床前和临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMEA":1},"content_text":"Biomea Fusion (BMEA) announced the presentation of preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies & Treatments for Diabetes 2025 Conference in Amsterdam, The Netherlands. The new findings support icovamenib’s potential as a first-in-class, disease-modifying therapy by targeting beta-cell restoration, enhancing insulin secretion, and sustaining glycemic improvements beyond icovamenib’s treatment period. Icovamenib, an investigational, covalent menin inhibitor, is being evaluated for its ability to restore pancreatic beta-cell mass and function, which are key drivers of disease progression in insulin-deficient diabetes. The presentations provided comprehensive insights into icovamenib’s mechanism of action, long-term clinical activity, biomarker responses, safety profile, and potential as a combination therapy with GLP-1-based medicines. ATTD 2025 Conference Highlights: First Large-Scale Analysis of C-Peptide Response: The data represents the first large-scale assessment of C-peptide levels in icovamenib-treated patients, providing robust evidence supporting its proposed mechanism of action. C-peptide, a key biomarker of endogenous insulin production, demonstrated significant increases, indicating improved pancreatic beta-cell function over 3 months after the final dose of icovamenib. OGTT-Based Beta-Cell Function Assessment: An oral glucose tolerance test was conducted at baseline and six timepoints over 26 weeks, providing a detailed evaluation of beta-cell insulin secretory capacity. This test is considered a robust and well-validated method of assessing beta cell insulin secretory capacity via assessment of the C-peptide index, the ratio of plasma C-peptide per unit of glucose. This offers critical insights into icovamenib’s impact on pancreatic beta-cell function. C-Peptide Increases in Insulin-Deficient Subgroups: Patients with insulin deficient diabetes experienced a mean increase in C-peptide index levels. In particular the severe insulin-deficient diabetes patients who received icovamenib experienced the largest mean increase in C-peptide index levels by Week 26. Long-Term Beta-Cell Restoration Potential: Insulin deficient patients who received icovamenib demonstrated a persistent increase in C-peptide levels beyond the active treatment period, over 3 months after the final dose of icovamenib, suggesting a durable effect on insulin secretion and reinforcing our belief in icovamenib’s potential to drive long-term improvements in beta-cell function. Strong Correlation between C-peptide and HbA1c: An analysis of the severe insulin-deficient diabetes subgroup of participants who were uncontrolled on at least one prior antihyperglycemic therapy revealed a strong correlation between changes in C-peptide index and HbA1c at Week 26. The strong correlation between the improvement in HbA1c and the increase in C-peptide index, 14 weeks after cessation of icovamenib therapy, supports the proposed mechanism of action of icovamenib, a durable improvement in beta-cell function. These data suggests that icovamenib fundamentally impacted the disease, potentially restoring the patient’s ability to produce more insulin, after a short treatment period. Precision Medicine Potential: Analysis across different diabetes subtypes demonstrated that icovamenib preferentially increased insulin secretion in insulin-deficient patients, highlighting its potential as a targeted therapy for individuals with severe insulin deficiency, a population with limited treatment options and the highest risk profile. Enhanced Impact of GLP-1 based Therapeutic Agents with Icovamenib Combination: Icovamenib enhanced responsiveness of human islets to the GLP-1-based medicines, semaglutide and tirzepatide. Enhancement in beta-cell function was correlated with an increase in the expression levels of the GLP-1 receptor as well as intracellular insulin – both transcript and protein levels were increased. These effects induced by icovamenib may allow lower doses of GLP-1-based medicines to achieve glycemic targets, potentially improving tolerability of these agents.\nLight Up your Portfolio with Spark:\n\nEasily identify stocks' risks and opportunities.\n Discover stocks' market position with detailed  competitor analyses.\n\n\nPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>\n\n\nSee Insiders’ Hot Stocks on TipRanks >> \n\n\nRead More on BMEA:Questions or Comments about the article? Write to editor@tipranks.com \n \nBiomea Fusion reports inducement grant under Nasdaq listing rule\nIs BMEA a Buy, Before Earnings?\nBiomea Fusion CFO Franco Valle Resigns\nBiomea Fusion to unveil ew icovamenib data at ATTD 2025","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522507626"}